Why are several oocytes collected instead of one in IVF?

Not every oocyte fertilizes, develops into a usable embryo, or implants, so retrieving several oocytes from a stimulated cycle increases the chance that at least one viable embryo is available for transfer and improves the cumulative yield of a treatment course.

What is ovarian hyperstimulation syndrome?

It is the main complication specific to ovarian stimulation, in which an exaggerated response to the drugs leads to enlarged ovaries and fluid shifts into body cavities. The risk of this syndrome is a key reason stimulation is carefully monitored and influences which protocol is chosen, though management itself is outside the scope of this reference entry.

Ovulation Induction and Controlled Ovarian Hyperstimulation

Ovulation induction uses hormonal agents to trigger the development and release of an oocyte in people who do not ovulate regularly, while controlled ovarian stimulation (often called controlled ovarian hyperstimulation) deliberately recruits multiple follicles to grow at once so that several oocytes can be retrieved for in vitro fertilization. Both rest on manipulating the gonadotrophin signals that normally govern the ovarian cycle.

Definition

Ovulation induction is the pharmacological stimulation of follicular development and ovulation, typically to restore ovulation in anovulatory individuals. Controlled ovarian stimulation is the related use of gonadotrophins, with suppression of the endogenous luteinizing-hormone surge, to grow a cohort of follicles and obtain multiple mature oocytes for assisted reproduction.

Scope

The topic covers the rationale for stimulating follicle growth, the main drug classes used to do so, the gonadotrophin agonist and antagonist protocols that prevent premature ovulation, how the response is monitored, and the spectrum of response from poor responders to those at risk of ovarian hyperstimulation syndrome. It treats stimulation as a methodological stage of ART, not as a prescribing guide.

Core questions

How is the natural single-follicle selection of the menstrual cycle overridden to recruit multiple follicles?
Why are GnRH agonists or antagonists used alongside gonadotrophins, and how do the protocols differ?
What distinguishes a poor responder from a high responder, and how is response anticipated?
What is ovarian hyperstimulation syndrome, and how does it arise from stimulation?

Key concepts

FSH threshold and window for follicle recruitment
Gonadotrophins (FSH, hMG)
GnRH agonist protocols
GnRH antagonist protocols
Premature LH surge suppression
Ovulation trigger (hCG or GnRH agonist)
Poor and high ovarian response
Ovarian hyperstimulation syndrome (OHSS)

Mechanisms

In a natural cycle a transient rise in follicle-stimulating hormone (FSH) above a threshold recruits a cohort of follicles, but only the most sensitive becomes dominant while the rest undergo atresia. Stimulation protocols sustain FSH above this threshold with exogenous gonadotrophins so that several follicles continue to grow together. To prevent the endogenous luteinizing-hormone surge from triggering ovulation before the oocytes are retrieved, pituitary signalling is controlled with a gonadotrophin-releasing hormone (GnRH) agonist, which first stimulates then desensitizes the pituitary, or a GnRH antagonist, which blocks it directly and rapidly; meta-analysis indicates the two strategies yield broadly comparable outcomes with differing risk profiles (Kadoura et al., 2022). Final oocyte maturation is then triggered, after which retrieval is timed. Individuals differ widely in their response, from poor responders who yield few oocytes (Oudendijk et al., 2012) to high responders at risk of ovarian hyperstimulation syndrome.

Clinical relevance

Stimulation determines how many oocytes are available for an ART cycle and is a major source of both treatment success and treatment risk, so its concepts underpin how outcomes and complications are understood. This entry explains the biology and study of stimulation for reference; it does not provide drug regimens, doses, or individualized treatment advice.

Epidemiology

Response to stimulation varies with ovarian reserve and age: poor responders are a recognized and prognostically important group whose outlook is not uniformly poor (Oudendijk et al., 2012), while the number of oocytes obtained contributes to the cumulative live-birth rate achievable from a single stimulation (Moragianni & Penzias, 2010). Ovarian hyperstimulation syndrome is the principal stimulation-specific complication, and its risk shapes protocol choice and monitoring.

Evidence & guidelines

Randomized trials and systematic reviews, including Cochrane syntheses and meta-analyses comparing agonist and antagonist protocols (Kadoura et al., 2022), form the core evidence; professional societies such as ESHRE and ASRM publish guidance on stimulation and on preventing ovarian hyperstimulation syndrome. Specific regimens are deliberately not reproduced here.

History

Pharmacological ovulation induction developed in the mid-twentieth century with the introduction of clomiphene citrate and of human menopausal gonadotrophins extracted from urine, which made it possible to stimulate follicular growth directly. The advent of IVF created the need to obtain several oocytes at once, and the later introduction of GnRH agonists and then antagonists gave clinicians control over the timing of ovulation, allowing the structured stimulation protocols now used in assisted reproduction.

Debates

GnRH agonist versus antagonist protocols: Agonist long protocols and antagonist protocols are both widely used; meta-analyses generally find comparable pregnancy outcomes, with antagonist protocols associated with a lower risk of ovarian hyperstimulation syndrome, so the optimal choice for different patient groups remains debated.
How best to define and manage poor responders: Poor ovarian response has been defined inconsistently, complicating both research and counselling; systematic review shows the prognosis is not uniformly poor, which questions blanket pessimism and supports tailored rather than fixed approaches.

Seminal works

kadoura-2022
oudendijk-2011

Frequently asked questions

Why are several oocytes collected instead of one in IVF?: Not every oocyte fertilizes, develops into a usable embryo, or implants, so retrieving several oocytes from a stimulated cycle increases the chance that at least one viable embryo is available for transfer and improves the cumulative yield of a treatment course.
What is ovarian hyperstimulation syndrome?: It is the main complication specific to ovarian stimulation, in which an exaggerated response to the drugs leads to enlarged ovaries and fluid shifts into body cavities. The risk of this syndrome is a key reason stimulation is carefully monitored and influences which protocol is chosen, though management itself is outside the scope of this reference entry.